P/E ratio for Innoviva (INVA)
P/E ratio as of June 2023 (TTM): 4.29
According to Innoviva's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 4.2899. At the end of 2021 the company had a P/E ratio of 5.51.
P/E ratio history for Innoviva from 2005 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 5.51 | -1.25% |
| 2020 | 5.58 | -39.3% |
| 2019 | 9.19 | 106.03% |
| 2018 | 4.46 | -60.37% |
| 2017 | 11.3 | -42.11% |
| 2016 | 19.5 | -129.53% |
| 2015 | -65.9 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | -3.82 | -188.95% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | -1.38 | -132.15% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.